Drug intelligence / Profile preview

dominant-negative STAT5 adenovirus

Development stage: Discontinued
Modality: Gene Therapies
Administration: Intratumoral

Overview

Dn-Stat5 adenovirus (Ad-DN-STAT5) is a recombinant adenoviral vector expressing a dominant-negative mutant of Signal Transducer and Activator of Transcription 5 (STAT5), typically a carboxyl-truncated variant (such as Stat5a-Δ713 or Stat5a-Δ740) that lacks the C-terminal transactivation domain. This construct retains the ability to dimerize and bind DNA but is transcriptionally inactive, thereby acting as a dominant-negative inhibitor of endogenous STAT5a and STAT5b signaling. It is widely used as a research-use-only laboratory tool to investigate the role of STAT5 in cell growth, differentiation, survival, and apoptosis across various models, including breast cancer, prostate cancer, and neuronal systems.

Other names: Ad-DN-STAT5Ad-DN-STAT-5Ad-DN-STAT 5Ad-DN-STAT5aAd-DN-STAT-5aAd-DN-STAT 5aAd-DN-STAT5a/bAdStat5aDelta713AdStat-5aDelta713AdStat 5aDelta713AdStat5aDelta740AdStat-5aDelta740AdStat 5aDelta740AdStat5aDelta749AdStat-5aDelta749AdStat 5aDelta749Dn-Stat5 adenovirusDn-Stat-5 adenovirusDn-Stat 5 adenovirusdominant-negative STAT5 adenovirus

Targets

STAT5A (STAT5)

Beyond the preview

Go deeper on dominant-negative STAT5 adenovirus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dominant-negative STAT5 adenovirus.

Explore the full profile